

U.S. Food and Drug Administration Division of Pharmaceutical Quality Operations III 300 River Place, Suite 5900 Detroit, MI 48207 Telephone: (313) 393-8100 Fax: (313) 393-8139 www.fda.gov

October 22, 2019

<u>UPS NEXT DAY</u> SIGNATURE REQUIRED

Stephen G. Anderson, R.Ph.OwnerW & C Apothecary dba The Apothecary 165 19th Street South, Suite 102Sartell, MN 56377-2567

Dear Mr. Anderson:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, W & C Apothecary dba The Apothecary, located at 165 19th Street South, Suite 102, Sartell, MN 56377, from July 23, 2018, to July 30, 2018, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Minnesota Board of Pharmacy for follow up.

When the Agency concludes that an inspection is "closed" under 21 CFR 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 CFR Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Nicholas Lyons at (312) 596-4220 or by email at: ORAPHARM3_RESPONSES@fda.hhs.gov.

Sincerely,



Nicholas F. Lyons Director Compliance Branch Division of Pharmaceutical Quality Operations III